Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial.
暂无分享,去创建一个
D. Salinger | K. Papp | R. Sinclair | Hua Dong | J. Krueger | C. Russell | P. Foley | David A. Martin | C. Reid | G. Williams | D. Martin
[1] S. Gaffen. Recent advances in the IL-17 cytokine family. , 2011, Current opinion in immunology.
[2] J. Krueger,et al. Anti-cytokine therapies for psoriasis. , 2011, Experimental cell research.
[3] S. Chimenti,et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. , 2011, The Journal of investigative dermatology.
[4] Yoichiro Iwakura,et al. Review Functional Specialization of Interleukin-17 Family Members , 2022 .
[5] P. Tak,et al. Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis , 2010, Science Translational Medicine.
[6] Mayte Suárez-Fariñas,et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. , 2009, The Journal of allergy and clinical immunology.
[7] S. Gaffen. Structure and signalling in the IL-17 receptor family , 2009, Nature Reviews Immunology.
[8] F. Nestle,et al. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. , 2009, The Journal of investigative dermatology.
[9] R. B. Kjellerup,et al. Characterization of the interleukin‐17 isoforms and receptors in lesional psoriatic skin , 2009, The British journal of dermatology.
[10] Lisa C. Zaba,et al. Th17 cytokines interleukin (IL)‐17 and IL‐22 modulate distinct inflammatory and keratinocyte‐response pathways , 2008, The British journal of dermatology.